OR WAIT 15 SECS
Critical comments of the drug evaluation process bring about strong reaction from industry.
In a recent analytical article and additional commentary published in BMJ, the drug evaluation process suffered heavy criticism. The controversial articles-which can be found below-elicited strong reactions from industry leaders including, Dr. Beat Widler, Professor Gerfried Nell, Dr. Uwe Gudat, and Thorsten Ruppert. Continue reading to hear clinical trials professionals defend and discuss the depictions made in the BMJ publications.
“Patients and the public deserve big changes in evaluation of drugs,” Silvio Garattini, director, Mario Negri Institute for Pharmacological Research, Via Giuseppe La Masa 19, 20156 Milan, Italy; and Iain Chalmers, editor, James Lind Library, 2 Summertown Pavilion, Oxford OX2 7LG, U.K.